Oral composition

Abstract

To provide an oral composition that can be used for anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, reduction or elevation suppression of blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, and suppression of adipocyte maturation. 【Solution means】An oral composition containing gallocatechinol and hydroxycitric acid, wherein the mass ratio of gallocatechinol to hydroxycitric acid in the composition is gallocatechinol:hydroxycitric acid = 1:0.01 to 10. The oral composition preferably further contains isogallocatechinol.

Description

Technical Field

[0001] The present invention relates to oral compositions and food and drink products.

Background Art

[0002] In recent years, in the lives of Japanese people, although the overall amount of physical activity has been on a downward trend, the energy intake from food shows a relatively excessive tendency. Therefore, there is a concern about becoming obese. In the past, many people became obese due to aging, but in recent years, obese young people have also become prominent. Since obesity can lead to more serious diseases such as arteriosclerosis and cancer, it is required to prevent or improve obesity in daily diet.

[0003] Based on such needs, various anti-obesity compositions that can be easily ingested in daily life have been developed. For example, Patent Document 1 describes an anti-obesity composition containing lime algae and globin proteolysate as active ingredients. However, since globin proteolysate has a specific taste, there are consumers who dislike its taste. Also, since people's preferences vary widely, there are consumers who are not satisfied with existing anti-obesity compositions from viewpoints other than taste. Therefore, the development of new oral compositions showing an anti-obesity effect has been demanded.

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0005] The present invention aims to provide a new oral composition that exhibits anti-obesity effects, body fat reduction effects, abdominal fat or visceral fat reduction effects, BMI reduction effects, blood triglyceride reduction or elevation suppression effects, blood cholesterol reduction effects, fat burning promotion effects, lipolysis promotion effects, energy consumption improvement effects, or fat accumulation suppression effects. [Means for Solving the Problems]

[0006] The inventor has found that in a composition containing garcinol and hydroxycitric acid, by setting the mass ratio of garcinol to hydroxycitric acid within a specific range, an oral composition having excellent anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, blood triglyceride reduction or elevation suppression, blood cholesterol reduction, fat burning promotion, lipolysis promotion, energy consumption improvement, or fat accumulation suppression can be obtained.

[0007] That is, the outline of the present invention is as follows. [1] An oral composition containing garcinol and hydroxycitric acid, wherein the mass ratio of garcinol to hydroxycitric acid in the composition is garcinol:hydroxycitric acid = 1:0.01 to 10. [2] The oral composition according to claim 1, which is used for one or more uses selected from anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, blood triglyceride reduction or elevation suppression, blood cholesterol reduction, lipolysis promotion, fat burning promotion, energy consumption improvement, fat accumulation suppression, and inhibition of adipocyte maturation. [3] The oral composition according to [1] or [2], further containing isogarcinol. [4] The oral composition according to [3], wherein the mass ratio of garcinol to isogarcinol is garcinol:isogarcinol = 1:0.01 to 10. [5] A food or drink product containing garcinol as an active ingredient, further containing hydroxycitric acid, wherein the mass ratio of garcinol to hydroxycitric acid in the food or drink product is garcinol:hydroxycitric acid = 1:0.01 to 10, and is labeled as having one or more functions selected from anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, blood triglyceride reduction or increase inhibition, blood cholesterol reduction, fat decomposition promotion, fat combustion promotion, energy consumption improvement, fat accumulation inhibition, and fat cell maturation inhibition. [6] A food or drink product containing garcinol as an active ingredient, further containing hydroxycitric acid and isogarcinol, wherein the mass ratio of garcinol to hydroxycitric acid in the food or drink product is garcinol:hydroxycitric acid = 1:0.01 to 10, and is labeled as having one or more functions selected from anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, blood triglyceride reduction or increase inhibition, blood cholesterol reduction or increase inhibition, fat decomposition promotion, fat combustion promotion, energy consumption improvement, fat accumulation inhibition, and fat cell maturation inhibition. [7] The food or drink product according to [6], wherein the mass ratio of garcinol to isogarcinol is garcinol:isogarcinol = 1:0.01 to 10. [8] The food or drink product according to any one of [5] to [7], which is a functional food or a food for specified health use.

Advantages of the Invention

[0008] According to the present invention, an oral composition containing gallocatechin and hydroxycitric acid can be provided. In particular, it can provide an oral composition such as a food or drink product that is effective for use in anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, reduction or suppression of increase in blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, or suppression of adipocyte maturation.

Embodiments for Carrying Out the Invention

[0009] Hereinafter, preferred embodiments of the oral composition of the present invention will be described. The oral composition of the present invention contains gallocatechin as an active ingredient with respect to functions related to anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, reduction or suppression of increase in blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, and suppression of adipocyte maturation.

[0010] 1. Garcinol The gallocatechin used in the present invention is a compound that is a type of polyisoprenylated benzophenone derivative. Gallocatechin is known to have effects such as anti-obesity and body fat reduction, and also functions as an active ingredient in the composition of the present invention. The gallocatechin used in the present invention is not particularly limited as long as it can be used as a food or drink product, and plant-derived gallocatechin or those obtained by synthesis can be used. When plant-derived gallocatechin is used in the composition of the present invention, as a gallocatechin source, plant extracts or ground powders may be used, or purified products thereof may be used. As the plant extract, an extract with concentrated gallocatechin to increase the concentration may be used. In the present application, the plant extract includes both an extract obtained by extracting a plant with a solvent and an extract obtained by squeezing a plant, and is a concept including those obtained by drying the extracted or squeezed extract and pulverizing it into a powder. Also, in the present application, the plant ground powder refers to a powder obtained by drying and pulverizing a plant.

[0011] The content of gallocatechin in the oral composition of the present invention is not particularly limited. However, from the viewpoint of further enhancing the functions related to anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, reduction or suppression of increase in blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, and suppression of adipocyte maturation, it is preferably 0.0005 to 60 parts by mass, more preferably 0.005 to 50 parts by mass, still more preferably 0.05 to 40 parts by mass, particularly preferably 0.1 to 30 parts by mass, and most preferably 0.3 to 20 parts by mass in the solid content of the oral composition. In this specification, the solid content refers to the content in the composition when the composition is in a solid state, and when the composition is in a liquid or fluid state, it refers to the total amount of all components excluding water in the composition.

[0012] The content of gallocatechin in the composition of the present invention can be measured by the HPLC method. For example, it can be measured as follows using an HPLC analyzer (equipped with an ultraviolet absorption detector), an analytical column manufactured by Imtakt Corporation (Imtakt Unison UK-C18 HT 3μm φ3×150mm), and a membrane filter (0.45μm). Note that devices having equivalent functions can be substituted.

[0013] [Standard] Gallocatechin

[0014] [Reagents Used] Acetic acid (special grade), acetonitrile (for HPLC, special grade). Reagents having equivalent purity can be substituted.

[0015] [Preparation of Standard Solution] Precisely weigh about 10 mg of the standard, dissolve it in acetonitrile, and prepare solutions with concentrations of 0.02, 0.04, and 0.2 mg / mL. Those filtered through a membrane filter are used as standard solutions. Note that appropriate treatment may be carried out as necessary, such as removing impurities in the sample to conform to the separation ability of the device.

[0016] [Preparation of Sample Solution] When the sample whose content is to be measured is solid, after making it uniform by grinding in a mortar etc., accurately weigh about 50 mg, add acetonitrile to make it exactly 50 mL, and use the filtered solution through a membrane filter as the sample solution. When the sample is liquid, adjust the appropriate amount according to the gallocatechol concentration in the sample, add acetonitrile to make it exactly 50 mL, and use the filtered solution through a membrane filter as the sample solution.

[0017] [HPLC Operating Conditions] Analytical column: Imtakt Unison UK-C18 HT 3μm φ3×150mm Column temperature: 40°C Injection volume: 5 μL Flow rate: 1.0 mL / min Measurement wavelength: 350 nm Mobile phase A: 0.1% aqueous acetic acid solution Mobile phase B: Acetonitrile

[0018] The gradient conditions are shown in Table 1.

[0019]

Table 1

[0020] By analyzing under the above conditions, chromatograms of the standard solution and the sample solution are obtained. A calibration curve is created from the gallocatechol peak area and concentration of the standard solution, and the content of gallocatechol in the composition is measured by determining the gallocatechol concentration (mg / mL) in the sample solution from the calibration curve.

[0021] 2. Hydroxycitric acid The composition of the present invention contains hydroxycitric acid. Hydroxycitric acid is a derivative of citric acid and is a compound having a structure in which the 1-position is hydroxylated. The hydroxycitric acid used in the present invention is not particularly limited as long as it can be used as a food or drink, and plant-derived hydroxycitric acid or those obtained by synthesis can be used. When plant-derived hydroxycitric acid is used in the composition of the present invention, plant extracts or ground powders may be used as the hydroxycitric acid source, or purified products thereof may be used. Further, the hydroxycitric acid used in the present invention may be in the form of a salt. When a salt of hydroxycitric acid is used in the present invention, for example, calcium hydroxycitrate can be mentioned. In the present invention, when a salt is used as hydroxycitric acid, the amount of hydroxycitric acid is the amount in terms of hydroxycitric acid.

[0022] In the present invention, the inventor believes that hydroxycitric acid is an auxiliary component that enhances the effect of gallocatechin. In order to exhibit the effects of both components, it is necessary to set the mass ratio of gallocatechin to hydroxycitric acid in the composition of the present invention to gallocatechin:hydroxycitric acid = 1:0.01 to 10. As shown in the examples described later, in the present invention, in an oral composition, by containing gallocatechin and hydroxycitric acid at a specific mass ratio, functions such as anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, reduction or increase suppression of blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, and suppression of adipocyte maturation can be effectively enhanced.

[0023] In the composition of the present invention, the mass ratio of gallocatechin to hydroxycitric acid is not particularly limited as long as it is in the range of gallocatechin:hydroxycitric acid = 1:0.01 to 10. However, from the viewpoint of further enhancing the effects of the present invention, the lower limit of the mass of hydroxycitric acid relative to 1 part by mass of gallocatechin is preferably 0.02 part by mass or more, more preferably 0.03 part by mass or more, still more preferably 0.05 part by mass or more, particularly preferably 0.08 part by mass or more, and most preferably 0.1 part by mass or more. Also, from the viewpoint of further enhancing the effects of the present invention, the upper limit of the mass of hydroxycitric acid relative to 1 part by mass of gallocatechin is preferably 9 parts by mass or less, more preferably 5 parts by mass or less, still more preferably 3 parts by mass or less, particularly preferably 1 part by mass or less, and most preferably 0.5 part by mass or less.

[0024] The content of hydroxycitric acid in the oral composition of the present invention is not particularly limited. However, from the viewpoint of further enhancing the functions related to anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, reduction or suppression of increase in blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, and suppression of adipocyte maturation, it is preferably 0.0005 to 30 parts by mass, more preferably 0.001 to 25 parts by mass, still more preferably 0.005 to 20 parts by mass, particularly preferably 0.01 to 15 parts by mass, and most preferably 0.05 to 10 parts by mass in the solid content of the oral composition.

[0025] The content of hydroxycitric acid in the composition of the present invention can be measured by the HPLC method. For example, it can be measured as follows using an HPLC analyzer (equipped with an ultraviolet absorption detector), an analytical column manufactured by Showa Denko K.K. (Shorex RSpak KC-811×2, φ8.0 mm × 300 mm), and a membrane filter (0.45 μm). Note that devices having equivalent functions can be substituted.

[0026] [Standard] (-) - Hydroxycitric acid calcium salt standard

[0027] [Preparation of standard solution] After weighing a certain amount of the standard, dissolve it in 5% perchloric acid and prepare it so that the concentrations are 0.5, 0.2, and 0.01 mg / mL. Those filtered through a membrane filter are used as the standard solution. In addition, appropriate treatment may be carried out as necessary, such as removing impurities in the sample to conform to the separation ability of the apparatus.

[0028] [Preparation of sample solution] Crush the sample with a mill, accurately weigh about 200 mg, add 10 mL of 1 mol / L sodium hydroxide solution, mix, and warm. After cooling, add 10 mL of 1 mol / L hydrochloric acid and 20 mL of 5% perchloric acid, mix, make it exactly 200 mL with water, and use the filtered solution through a membrane filter as the sample solution.

[0029] [Operating conditions of HPLC] Analytical column: Shorex RSpak KC-811×2, φ8.0 mm×300 mm Column temperature: 40 °C Injection volume: 20 μL Flow rate: 1.0 mL / min Measurement wavelength: 220 nm Mobile phase: 3 mmol·L perchloric acid

[0030] By analyzing under the above conditions, chromatograms of the standard solution and the sample solution are obtained. A calibration curve is created from the peak height and concentration of the standard solution, and the content of hydroxycitric acid in the composition is measured by determining the concentration (mg / mL) of hydroxycitric acid in the sample solution from the calibration curve.

[0031] 3. Isogarcinol From the perspective of further enhancing the functions related to anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, reduction or suppression of increase in blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, and suppression of adipocyte maturation, it is more preferable that the oral composition of the present invention further contains isogarcinol. Isogarcinol is a kind of compound of polyisoprenylated benzophenone. The isogarcinol used in the present invention is not particularly limited as long as it can be used as a food or drink, and plant-derived isogarcinol or those obtained by synthesis can be used. When plant-derived isogarcinol is used in the composition of the present invention, as the isogarcinol source, plant extracts or pulverized powders may be used, or purified products thereof may be used.

[0032] When the oral composition of the present invention contains isogarcinol, the lower limit of the mass of isogarcinol relative to 1 part by mass of garcinol is not particularly limited, but from the perspective of further enhancing the effects of the present invention, it is preferably 0.01 part by mass or more (garcinol:isogarcinol = 1:0.01 or more), more preferably 0.02 part by mass or more, still more preferably 0.03 part by mass or more, particularly preferably 0.04 part by mass or more, and most preferably 0.05 part by mass or more. Also, the upper limit of the mass of isogarcinol relative to 1 part by mass of garcinol is not particularly limited, but from the perspective of further enhancing the effects of the present invention, it is preferably 10 parts by mass or less (garcinol:isogarcinol = 1:10 or less), more preferably 5 parts by mass or less, still more preferably 3 parts by mass or less, particularly preferably 1 part by mass or less, and most preferably 0.5 part by mass or less.

[0033] When the oral composition of the present invention contains isogarcinol, the content of isogarcinol in the oral composition is not particularly limited. However, from the viewpoint of further enhancing the functions related to anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, reduction or increase suppression of blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, and suppression of adipocyte maturation, it is preferably 0.0005 to 25 parts by mass, more preferably 0.001 to 20 parts by mass, still more preferably 0.005 to 15 parts by mass, particularly preferably 0.01 to 10 parts by mass, and most preferably 0.03 to 7 parts by mass in the solid content of the oral composition.

[0034] The content of isogarcinol in the composition of the present invention can be measured by the HPLC method. For example, it can be measured as follows using an HPLC analyzer (equipped with an ultraviolet absorption detector), an analytical column manufactured by Imtakt Corporation (Imtakt Unison UK-C18 HT 3μm φ3×150mm), and a membrane filter (0.45μm). Note that devices having equivalent functions can be substituted.

[0035] [Standard] Isogarcinol

[0036] [Reagents Used] Acetic acid (special grade), acetonitrile (for HPLC, special grade). Reagents having equivalent purity can be substituted.

[0037] [Preparation of Standard Solution] Precisely weigh about 1 mg of the standard, dissolve it in acetonitrile, and prepare it so that the concentrations are 0.02 and 0.04 mg / mL. Those filtered through a membrane filter are used as the standard solution. Note that appropriate treatment may be carried out as necessary, such as removing impurities in the sample to conform to the separation ability of the device.

[0038] [Preparation of Sample Solution] When the sample to be measured for content is a solid, after making it uniform by grinding in a mortar etc., accurately weigh about 30 mg, add acetonitrile to make it exactly 50 mL, and use the filtered solution through a membrane filter as the sample solution. When the sample to be measured is a liquid, adjust the appropriate amount according to the isogarcinol concentration in the sample, add acetonitrile to make it exactly 50 mL, and use the filtered solution through a membrane filter as the sample solution.

[0039] [HPLC Operating Conditions] Analysis column: Imtakt Unison UK-C18 HT 3μm φ3×150mm Column temperature: 40 °C Injection volume: 5 μL Flow rate: 1.0 mL / min Measurement wavelength: 278 nm Mobile phase A: 0.1% aqueous acetic acid solution Mobile phase B: Acetonitrile

[0040] The gradient conditions are shown in Table 2.

[0041]

Table 2

[0042] By analyzing under the above conditions, chromatograms of the standard solution and the sample solution are obtained. A calibration curve is created from the isogarcinol peak area and concentration of the standard solution, and the content of isogarcinol in the composition is measured by determining the isogarcinol concentration (mg / mL) in the sample solution from the calibration curve.

[0043] 4. Oral composition The oral composition of the present invention may contain components other than gallocatechin, hydroxycitric acid, and isogallocatechin. Examples of such other components include saccharides, vitamins, minerals, proteins, dietary fibers such as insoluble dietary fiber, plants or processed plant products, yeast, and the like. Further, if necessary, sweeteners, acidulants, colorants, thickeners, brighteners, lubricants, excipients, anti-caking agents, dietary supplements, binders, lubricants, stabilizers, diluents, bulking agents, emulsifiers, food additives, seasonings, and the like, which are usually used in the food field, may be contained.

[0044] Examples of the form of the oral composition of the present invention include tablets, capsules, powders, granules, liquids, granular agents, rod-shaped agents, plate-shaped agents, block-shaped agents, solid-shaped agents, spherical agents, paste-shaped agents, cream-shaped agents, caplet-shaped agents, gel-shaped agents, chewable agents, stick-shaped agents, and the like. Among these forms, from the viewpoint of ease of administration, the forms of tablets, capsules, powders, granules, and liquids are preferable.

[0045] Specific examples of the form of the oral composition of the present invention include pharmaceuticals (including quasi-drugs) and food and drink products. Among them, from the viewpoint of being easily ingestible in daily life, it is particularly preferable that it is a food and drink product.

[0046] Examples of the food and drink products of the present invention include so-called health foods such as general foods, foods with nutritional functions, foods with functional claims whose efficacy has been approved by a prescribed agency, and foods for specified health use. Foods with displayed efficacy may sometimes be collectively referred to as "health functional foods" or "functional foods". When the oral composition of the present invention is a food and drink product, from the viewpoint of being able to convey the effects of the present invention to consumers, it is particularly preferable that it is a food with functional claims or a food for specified health use.

[0047] The food and drink of the present invention are not particularly limited, and examples include milk and dairy products; beverages such as soft drinks, fruit juices, milk drinks, alcoholic beverages, sports drinks, and nutritional drinks; seasonings; liquors; agricultural and forestry processed foods; confectionery and breads; cereal flours and noodles; fishery processed products; livestock processed products; fats and oil processed products; frozen cooked foods; retort foods; instant foods; food materials; supplements, etc. As the form of the supplement, for example, tablet form, capsule form, powder form, granular form, liquid form, etc. can be mentioned.

[0048] 5. Oral composition used for applications such as anti-obesity As shown in the examples described later, the oral composition of the present invention suppresses fat accumulation in adipocytes. Therefore, the oral composition of the present invention is preferably used for one or more uses selected from (1) anti-obesity, (2) body fat reduction, (3) reduction of visceral abdominal fat or visceral fat, (4) reduction of BMI (Body Mass Index), (5) reduction or suppression of increase in blood triglycerides, (6) reduction of blood cholesterol, (7) promotion of fat decomposition, (8) promotion of fat burning, (9) improvement of energy consumption, (10) suppression of fat accumulation, (11) suppression of adipocyte maturation. Therefore, the composition of the present invention can be used as (1) a composition for anti-obesity, (2) a composition for body fat reduction, (3) a composition for reduction of abdominal fat or visceral fat, (4) a composition for reduction of BMI (Body Mass Index), (5) a composition for reduction or suppression of increase in blood triglycerides, (6) a composition for reduction of blood cholesterol, (7) a composition for promotion of fat decomposition, (8) a composition for promotion of fat burning, (9) a composition for improvement of energy consumption, (10) a composition for suppression of fat accumulation, (11) a composition for suppression of adipocyte maturation.

[0049] In the present invention, (1) "anti-obesity" includes the action of suppressing (maintaining) the increase in body weight or body fat and the action of reducing body weight or body fat, and includes not only the action on patients with obesity as a disease, but also the action of suppressing or reducing the increase in body weight and body fat in overweight people, as well as the diet effect and slimming effect for cosmetic purposes.

[0050] In the present application, "body fat" refers to the fat in the body and is a general term for visceral fat and subcutaneous fat. That is, in the present invention, (2) "body fat reduction" means an action of reducing the amount of body fat (visceral fat or subcutaneous fat; abdominal fat and total abdominal fat are also included in body fat).

[0051] In the present invention, (3) "abdominal fat or visceral fat reduction" means an action of reducing the amount of abdominal fat or visceral fat.

[0052] In the present invention, (4) "BMI reduction" means reducing the value of BMI.

[0053] In the present invention, (5) "reduction or suppression of increase in blood triglyceride" means reducing the concentration of blood triglyceride on an empty stomach or after a meal or suppressing its increase.

[0054] In the present invention, (6) "reduction of blood cholesterol" means reducing the concentration of cholesterol in the blood.

[0055] In the present invention, (7) "promotion of fat decomposition" means promoting the decomposition of fat (triglyceride) in the body.

[0056] In the present invention, (8) "promotion of fat burning" means promoting the metabolism of decomposing fat (triglyceride) in the body and converting it into energy for consumption.

[0057] In the present invention, (9) "improvement of energy consumption" means improving the energy consumption in the body by burning fat or sugar in the body.

[0058] In the present invention, (10) "suppression of fat accumulation" means suppressing the accumulation of fat in the body.

[0059] In the present invention, (11) "suppression of adipocyte maturation" means suppressing the maturation of adipocytes in the body.

[0060] (1) to (11) function as follows. As described below, the composition of the present invention has an action of suppressing fat accumulation in (10) adipocytes. Therefore, it exhibits the effects of (1) anti-obesity, (2) body fat reduction, (3) abdominal fat or visceral fat reduction, and (4) BMI reduction. Also, in the tests described below, it has been confirmed that the composition of the present invention suppresses the accumulation of lipid droplets (an index of fat content). Since lipid droplets are composed of neutral fat (triglyceride), cholesterol ester, etc., the composition of the present invention also exhibits effects such as (5) reduction or increase suppression of blood neutral fat and (6) reduction of blood cholesterol.

[0061] Regarding the mechanism of fat accumulation suppression, it is considered that fatty acids generated by the decomposition of fat in adipocytes are transported to other tissues via blood vessels and consumed as an energy source (Takashi Oomi, Fat Metabolism and Its Regulation - Energy Balance of the Body - Research Introduction Materials for the University Open Lecture in 2008 at Hyogo Prefectural University; URL: https: / / www.sci.u-hyogo.ac.jp / life / molbio / KOKAI.pdf). Therefore, the fat accumulation suppression action is regarded as an index of fat decomposition promotion. For example, in Japanese Patent No. 7428430 (Cosfa Co., Ltd.), the fat decomposition promotion action is evaluated by a fat accumulation suppression confirmation test. Therefore, when the composition of the present invention suppresses fat accumulation in adipocytes, effects such as (7) promotion of fat decomposition, (8) promotion of fat burning, and (9) improvement of energy consumption are exhibited. Note that adipocytes mature into mature adipocytes that accumulate fat intracellularly after differentiating from stem cells and progenitor cells (Teruo Kawata, Obesity and Lifestyle-Related Diseases: The Merits and Demerits of Adipocytes; Micronutrient Research 22, 2005: 1-5 pages, URL: https: / / www.jstage.jst.go.jp / article / jtnrs / 22 / 0 / 22_1 / _pdf). Therefore, when fat accumulation is inhibited, they cannot mature. Therefore, the composition of the present invention also exhibits the effect of (11) suppressing adipocyte maturation.

[0062] From the viewpoint of enhancing functions related to anti-obesity, body fat reduction, abdominal fat or visceral fat reduction, BMI reduction, reduction or increase suppression of blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, and suppression of adipocyte maturation, the oral composition of the present invention preferably contains 1 to 1000 mg of gallocatechin per adult per day, more preferably 5 to 200 mg, and most preferably 10 to 100 mg.

[0063] When the oral composition of the present invention is an oral composition used for any of the functions (1) to (11) described above, it contains gallocatechin and hydroxycitric acid in a specific mass ratio, and in that it is used for any of the functions (1) to (11), it is not particularly limited as long as it can be distinguished from other products as a product. For example, if any of the product body, packaging, instruction manual, or promotional materials (advertising media) of the product according to the present invention displays any of the functions (1) to (11), it is included in the scope of the present invention. The oral composition used for any of the functions (1) to (11) of the present invention may display gallocatechin as an active ingredient, but it is not limited to those in which gallocatechin is displayed as an active ingredient on the packaging of the product, etc. For example, it may not specify the active ingredient. Also, even general foods that are manufactured and sold suggesting any of the uses (1) to (11) are included in the scope of the present invention. For example, foods sold with testimonials on a homepage, etc., that mention the maintenance and / or improvement of any of the functions (1) to (11) as the personal impressions of the consumers who have ingested them are also included in the scope of the present invention. Also, functional foods with papers, etc., showing the maintenance and / or improvement of any of the functions (1) to (11) as the scientific basis for functionality and gallocatechin as a functional-related ingredient, and functional foods with a notification display of functionality related to any of (1) to (11) are also included in the scope of the present invention. As described above, since components other than gallocatechin in the present invention are auxiliary components for enhancing the effect of gallocatechin, they are usually not displayed as involved components in functional foods with a notification display of any of the functions (1) to (11) or foods for specified health use. However, the oral composition used for any of the functions (1) to (11) in the present invention does not exclude those in which auxiliary components such as hydroxycitric acid and isogallocatechin are displayed as involved components, and functional foods with a notification display of hydroxycitric acid, etc., as an involved component are also included in the oral composition.

[0064] As described above, the oral composition used for any of the functions (1) to (11) includes food and drink products labeled with having one or more functions selected from anti-obesity, body fat reduction, abdominal fat and visceral fat reduction, BMI reduction, blood triglyceride reduction and elevation suppression, blood cholesterol reduction, fat burning promotion, energy consumption improvement, and fat accumulation suppression. As such food and drink products, it is particularly preferable that they are foods with functional claims or foods for specified health use.

[0065] Examples of food and drink products labeled with having one or more functions selected from (1) to (11) include food and drink products that appeal to those concerned about obesity, body fat, abdominal circumference, weight, abdominal fat (such as visceral fat and subcutaneous fat), BMI, etc., such as those who are overweight, worried about their obesity, concerned about their abdominal circumference, concerned about their weight, concerned about their abdominal fat (visceral fat, subcutaneous fat, etc.), concerned about their BMI, etc. Also included are food and drink products labeled with having specific functions such as helping to reduce weight, helping to reduce body fat, helping to reduce abdominal fat (visceral fat, subcutaneous fat, total abdominal fat, etc.), helping to reduce waist circumference, helping to lower BMI, helping to eliminate obesity, making it easier to reduce fat, helping with dieting, supporting weight loss, supporting body fat reduction, supporting reduction of abdominal fat (visceral fat, subcutaneous fat, total abdominal fat, etc.), supporting reduction of waist circumference, supporting reduction of BMI, supporting elimination of obesity, supporting fat reduction, supporting dieting, helping to reduce blood triglycerides, suppressing the elevation of blood triglycerides, helping to reduce blood cholesterol, making it easier to burn fat, promoting fat burning, making it easier to consume energy, promoting energy consumption, making it difficult to accumulate fat, and suppressing fat accumulation.

Examples

[0066] Hereinafter, the present invention will be described based on examples. However, the present invention is not limited to the following examples. Unless otherwise specified, "parts" herein indicates "parts by mass" and "%" indicates "% by mass".

[0067] 1. Evaluation of fat accumulation inhibition The fat accumulation inhibition in adipocytes was evaluated by the method described below.

[0068] 1-(1). Obtaining of test substances The following substances were used as the test substances described in Tables 3 and 4. · Gallocatechin: Gallocatechin (purity 95% or higher) of a commercially available reagent was used. · Hydroxycitric acid: Hydroxycitric acid (purity 98% or higher) of a commercially available reagent was used. · Isogallocatechin: Isogallocatechin (purity 95% or higher) of a commercially available reagent was used.

[0069] 1-(2). Evaluation test for fat accumulation inhibition Using the above test substances, a cell test for evaluating fat accumulation inhibition was carried out according to the following procedures (a) to (g). (a) Mouse fibroblast 3T3-L1 was cultured in DMEM medium containing 10% (v / v) FBS using a 75 cm 2 flask in an incubator at 37°C and 5% by volume of CO2. (b) 3T3-L1 was suspended by trypsin treatment and seeded at a cell density of 2x10 2 cells / well in each well of a collagen-coated 96-well plate from a 75 cm 4 flask, and cultured in DMEM medium containing 10% (v / v) FBS in an incubator at 37°C and 5% by volume of CO2 until the cells became confluent. (c) Next, the medium was replaced with a differentiation induction medium containing the test sample of the example or comparative example (control was only the differentiation induction medium), and cultured for 2 days for differentiation induction. As the differentiation induction medium, DMEM medium containing 10% (v / v) FBS containing 0.5 mM isobutylmethylxanthine, 0.5 μM dexamethasone, and 10 μg / mL insulin was used. For each test sample, it was prepared in the differentiation induction medium so that the total amount of the test substance became a predetermined concentration (1 μg / mL). Tables 3 and 4 show the mass ratio of the test substance in each test sample. (d) The medium was replaced from the differentiation induction medium to a differentiation maintenance medium containing the test sample (control was only the differentiation maintenance medium), and cultured for 5 days. As the differentiation maintenance medium, DMEM medium containing 10% (v / v) FBS containing 10 μg / mL insulin was used. For each test sample, it was prepared in the differentiation maintenance medium so that the total amount of the test substance became a predetermined concentration (1 μg / mL). Tables 3 and 4 show the mass ratios of the test substances in each test sample. (e) After culturing in (d), the culture supernatant was removed and a 10% (v / v) formalin solution was added to fix the cells. (f) The lipid droplets generated by Oil Red staining were stained, and the absorbance of the extract was measured (520 nm and 650 nm). As a blank, wells without cells were also subjected to Oil Red staining in the same manner. Pierce TM The protein amount in each well was calculated using the Pierce BCA Protein Assay kit (Thermo Fisher Scientific). (g) From the following formula, the amount of lipid accumulation per protein was calculated, and the results of calculating the relative values with respect to the control are shown in Tables 3 and 4. The smaller the relative value, the more the lipid accumulation in adipocytes is suppressed. <Formula 1> Relative value of lipid accumulation amount (%) = [[(Abs520 sample - Abs520 blank) - (Abs650 sample - Abs650 blank) ] / (Protein sample)] / [(Abs520 control - Abs520 blank) - (Abs650 control - Abs650 blank) ] / (Protein control)]]×100 (%) Abs520 sample, Abs650 sample: Absorbance of each example or comparative example at 520 nm and 650 nm Abs520 control, Abs650 control: Absorbance of the control at 520 nm and 650 nm Abs520 blank, Abs650 blank: Absorbance of the blank at 520 nm and 650 nm Protein sample: Protein amount in cells in each example or comparative example Protein control: Protein amount in cells in the control

[0070] Furthermore, the suppression rate of fat accumulation was calculated from the following formula. The results are shown in Tables 3 and 4 <Formula 2> Suppression rate of fat accumulation (%) = 100 - relative value of fat accumulation

[0071]

Table 3

[0072]

Table 4

[0073] 1-(3). Results The results are shown in Tables 3 and 4. Even gallocatechin alone (Comparative Example 1) showed an effect of suppressing fat accumulation, but the effect was not so high. Also, no fat accumulation suppressing effect was observed with hydroxycitric acid alone (Comparative Example 2) or isogallocatechin alone (Comparative Example 3). Therefore, when gallocatechin and hydroxycitric acid were combined, it was expected that the effect would be lower than that of gallocatechin alone. However, surprisingly, in the compositions where the mass ratio of gallocatechin to hydroxycitric acid was gallocatechin:hydroxycitric acid = 1:0.01 to 10 (Examples 1 to 7), the fat accumulation suppressing effect was significantly improved compared to gallocatechin alone (Comparative Example 1). In particular, in the compositions where gallocatechin:hydroxycitric acid = 1:0.05 to 1 (Examples 2 to 5), the effect was particularly excellent. From this, it was found that by setting the mass ratio of gallocatechin to hydroxycitric acid in the composition in the range of gallocatechin:hydroxycitric acid = 1:0.01 to 10, the effect of gallocatechin can be enhanced. When the mass ratio of hydroxycitric acid to gallocatechin exceeded 1:10, the effect was not increased so much compared to gallocatechin alone (Comparative Examples 4 and 5). Moreover, the compositions containing garcinol and hydroxycitric acid in a predetermined mass ratio and containing isogarcinol (Examples 8 to 13) had a further improved effect of suppressing fat accumulation compared to the compositions containing garcinol and hydroxycitric acid in a predetermined mass ratio but not containing isogarcinol (Examples 1 to 7).

[0074] 2. Tablet of the present invention The raw materials were mixed so as to be in the ratios shown in Tables 5 and 6, and tablets (swallowable tablets) of Examples 14 to 43, each having a weight of 250 mg per tablet and a tablet diameter of 8 mm, were produced using a single-punch tableting machine. The compression pressure was set to 3 kN. By ingesting 2 tablets per day, the obtained tablets had the effects of anti-obesity, reduction of body fat, reduction of abdominal fat or visceral fat, reduction of BMI, reduction or suppression of increase of blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, and suppression of adipocyte maturation.

[0075] [Table 5]

[0076] [Table 6]

Claims

1. An oral composition containing garcinol and hydroxycitric acid, wherein the mass ratio of garcinol to hydroxycitric acid in the composition is garcinol:hydroxycitric acid = 1:0.01 to 9.

2. The oral composition according to claim 1, which is used for one or more applications selected from anti-obesity, reduction of body fat, reduction of abdominal fat or visceral fat, reduction of BMI, reduction of or suppression of increase in blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, and suppression of adipocyte maturation.

3. The oral composition according to claim 1 or 2, further containing isogarcinol.

4. A food or drink product having garcinol as an active ingredient, further containing hydroxycitric acid, wherein the mass ratio of garcinol to hydroxycitric acid in the food or drink product is garcinol:hydroxycitric acid = 1:0.01 to 9, and a food or drink product having indicated thereon that it has one or more functions selected from anti-obesity, reduction of body fat, reduction of abdominal fat or visceral fat, reduction of BMI, reduction of or suppression of increase in blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, and suppression of adipocyte maturation.

5. A food or drink product having garcinol as an active ingredient, further containing hydroxycitric acid and isogarcinol, wherein the mass ratio of garcinol to hydroxycitric acid in the food or drink product is garcinol:hydroxycitric acid = 1:0.01 to 9, and a food or drink product having indicated thereon that it has one or more functions selected from anti-obesity, reduction of body fat, reduction of abdominal fat or visceral fat, reduction of BMI, reduction of or suppression of increase in blood triglycerides, reduction of blood cholesterol, promotion of lipolysis, promotion of fat burning, improvement of energy consumption, suppression of fat accumulation, and suppression of adipocyte maturation.

6. The food or drink product according to claim 4 or 5, which is a food with functional claims or a food for specified health use.

Images